52 related articles for article (PubMed ID: 23519145)
1. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
3. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia Modulates Radiosensitivity and Response to Different Radiation Qualities in A549 Non-Small Cell Lung Cancer (NSCLC) Cells.
Nisar H; Labonté FM; Roggan MD; Schmitz C; Chevalier F; Konda B; Diegeler S; Baumstark-Khan C; Hellweg CE
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256084
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
[TBL] [Abstract][Full Text] [Related]
6. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
7. Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities.
Hendriks CM; Penning TM; Zang T; Wiemuth D; Gründer S; Sanhueza IA; Schoenebeck F; Bolm C
Bioorg Med Chem Lett; 2015 Oct; 25(20):4437-40. PubMed ID: 26372652
[TBL] [Abstract][Full Text] [Related]
8. Can lineage-specific markers be identified to characterize mesenchyme-derived cell populations in the human airways?
Singh SR; Billington CK; Sayers I; Hall IP
Am J Physiol Lung Cell Mol Physiol; 2010 Aug; 299(2):L169-83. PubMed ID: 20435685
[TBL] [Abstract][Full Text] [Related]
9. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract][Full Text] [Related]
10. Keratinocytes Exposed to Blue or Red Light: Proteomic Characterization Showed Cytoplasmic Thioredoxin Reductase 1 and Aldo-Keto Reductase Family 1 Member C3 Triggered Expression.
Lazzarini R; Tartaglione MF; Ciarapica V; Piva F; Giulietti M; Fulgenzi G; Martelli M; Ledda C; Vitale E; Malavolta M; Santarelli L; Bracci M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003379
[TBL] [Abstract][Full Text] [Related]
11. Analogues of Natural Chalcones as Efficient Inhibitors of AKR1C3.
Möller G; Temml V; Cala Peralta A; Gruet O; Richomme P; Séraphin D; Viault G; Kraus L; Huber-Cantonati P; Schopfhauser E; Pachmayr J; Tokarz J; Schuster D; Helesbeux JJ; Dyar KA
Metabolites; 2022 Jan; 12(2):. PubMed ID: 35208174
[TBL] [Abstract][Full Text] [Related]
12. In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.
Plavša JJ; Řezáčová P; Kugler M; Pachl P; Brynda J; Voburka Z; Ćelić A; Petri ET; Škerlová J
Acta Crystallogr F Struct Biol Commun; 2018 May; 74(Pt 5):300-306. PubMed ID: 29717998
[TBL] [Abstract][Full Text] [Related]
13. Depletion of signal recognition particle 72kDa increases radiosensitivity.
Prevo R; Tiwana GS; Maughan TS; Buffa FM; McKenna WG; Higgins GS
Cancer Biol Ther; 2017 Jun; 18(6):425-432. PubMed ID: 28494188
[TBL] [Abstract][Full Text] [Related]
14. Defining the biological functions and clinical significance of AKR1C3 in gastric carcinogenesis through multiomics functional analysis and immune infiltration analysis.
Shao Y; Yu X; Shan K; Yan J; Ye G
J Cancer; 2024; 15(9):2646-2658. PubMed ID: 38577596
[No Abstract] [Full Text] [Related]
15. A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F; Li WF; Jung D; Wang CC; Qi T; Shia CS; Hsu RY; Hsieh YC; Duan J
Am J Cancer Res; 2021; 11(7):3645-3659. PubMed ID: 34354865
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of AKR1C3 in Sodium Butyrate Treated G361 Cell.
Lee YJ; Choi YS; Kim S; Heo JY; Kim DS; Cho MK
Ann Dermatol; 2023 Dec; 35(6):468-471. PubMed ID: 38086362
[No Abstract] [Full Text] [Related]
17. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
18. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
19. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma.
Guo SS; Chen YZ; Liu LT; Liu RP; Liang YJ; Wen DX; Jin J; Tang LQ; Mai HQ; Chen QY
BMC Cancer; 2022 Aug; 22(1):880. PubMed ID: 35953777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
